Shionogi Of Japan Plans U.S. Focus On Metabolic Syndrome
This article was originally published in PharmAsia News
Japan's Shionogi acquired U.S.-based Sciele Pharma last year to give the Japanese firm a way to market its metabolic syndrome products, Shionogi President Isao Teshirogi says. He said his company wants to move away from its focus on antibiotics and give more emphasis to its medicines such as Crestor (rosuvastatin), marketed by AstraZeneca outside of Japan. Although Shionogi expects to continue to rely on Crestor as a major revenue source, the company faces a need for other sources of profit when the drug loses patent protection beginning in 2016. Teshirogi said the Sciele acquisition gives Shionogi a chance to use the U.S. firm's 800 medical representatives to sell an obesity drug it is developing. (Click here for more - a subscription may be required
You may also be interested in...
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.